NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs071180094

Registered date:29/03/2019

Treatment of fetal toxoplasmosis with pyrimethamine/sulfadiazine

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedFetal toxoplasmosis
Date of first enrollment18/06/2019
Target sample size35
Countries of recruitment
Study typeInterventional
Intervention(s)Treatment with un-licensed medicine

Outcome(s)

Primary OutcomeIncidence of infection at birth
Secondary Outcome1) incidence of intrauterine growth abnormality 2) incidence of congenital disorder 3) incidence of growth abnormality after birth 4) incidence of abdominal symptoms 5) incidence of pancytopenia 6) incidence of acute renal failure 7) incidence of hepatic dysfunction 8) incidence of skin eruption (e.g. erythema)

Key inclusion & exclusion criteria

Age minimum>= 16age old
Age maximumNot applicable
GenderBoth
Include criteriaConfirmed fetal toxoplasmosis (Toxoplasma DNA positive in amniotic fluid)
Exclude criteria#1 HIV positive patients #2 patients allergic to test compounds #3 patients with megaloblastic anemia due to folate deficiency #4 No consent is given from the patient him/herself nor a legally authorized representative/guardian of the patient #5 patients principal investigator judged inappropriate

Related Information

Contact

Public contact
Name Haruhiko Maruyama
Address 5200 Kihara, Kiyotake, Miyazaki 889-1692, JAPAN Miyazaki Japan 889-1692
Telephone +81-985-85-0990
E-mail hikomaru@med.miyazaki-u.ac.jp
Affiliation University of Miyazaki
Scientific contact
Name Haruhiko Maruyama
Address 5200 Kihara, Kiyotake, Miyazaki 889-1692, JAPAN Miyazaki Japan 889-1692
Telephone +81-985-85-0990
E-mail hikomaru@med.miyazaki-u.ac.jp
Affiliation University of Miyazaki Hospital